Stephan Maack

Senior Clinical Project Manager CR&D Hematology
Octapharma AG

Presentation(s):

• PB0559 - LEX-210: a phase 3, randomized, double-blinded study of four-factor prothrombin complex concentrate in patients with acute major bleeding on direct oral anticoagulant therapy with factor Xa inhibitors

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0560 - Use of heparin-calibrated assays to estimate anti-factor Xa activity of factor Xa inhibitors (FXaI): a literature correlation analysis

  Monday, July 11, 2022
  6:30 PM – 7:30 PM